• InterMune Inc., of Brisbane, Calif., said the Swedish Dental and Pharmaceutical Benefits Agency included Esbriet (pirfenidone) on the country's list of reimbursed drugs, making Esbriet the first therapeutic treatment for idiopathic pulmonary fibrosis to be reimbursed in Sweden.